Hydrochlorothiazide; lisinopril - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for hydrochlorothiazide; lisinopril and what is the scope of patent protection?
Hydrochlorothiazide; lisinopril
is the generic ingredient in three branded drugs marketed by Aurobindo, Chartwell Rx, Corepharma, Epic Pharma Llc, Hikma Intl Pharms, Invagen Pharms, Lupin, Norvium Bioscience, Prinston Inc, Sandoz, Sun Pharm Inds Ltd, Teva, Watson Labs, Merck, and Almatica, and is included in fifteen NDAs. Additional information is available in the individual branded drug profile pages.Thirty-four suppliers are listed for this compound.
Summary for hydrochlorothiazide; lisinopril
| US Patents: | 0 |
| Tradenames: | 3 |
| Applicants: | 15 |
| NDAs: | 15 |
| Finished Product Suppliers / Packagers: | 34 |
| Clinical Trials: | 12 |
| DailyMed Link: | hydrochlorothiazide; lisinopril at DailyMed |
Recent Clinical Trials for hydrochlorothiazide; lisinopril
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| The University of Texas Health Science Center, Houston | Phase 4 |
| IPCA Laboratories Ltd. | Phase 1 |
| Scripps Translational Science Institute | N/A |
Pharmacology for hydrochlorothiazide; lisinopril
| Drug Class | Angiotensin Converting Enzyme Inhibitor Thiazide Diuretic |
| Mechanism of Action | Angiotensin-converting Enzyme Inhibitors |
| Physiological Effect | Increased Diuresis |
Anatomical Therapeutic Chemical (ATC) Classes for hydrochlorothiazide; lisinopril
US Patents and Regulatory Information for hydrochlorothiazide; lisinopril
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Epic Pharma Llc | LISINOPRIL AND HYDROCHLOROTHIAZIDE | hydrochlorothiazide; lisinopril | TABLET;ORAL | 075926-001 | Jul 1, 2002 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Almatica | ZESTORETIC | hydrochlorothiazide; lisinopril | TABLET;ORAL | 019888-003 | Nov 18, 1993 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Merck | PRINZIDE | hydrochlorothiazide; lisinopril | TABLET;ORAL | 019778-002 | Feb 16, 1989 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Corepharma | LISINOPRIL AND HYDROCHLOROTHIAZIDE | hydrochlorothiazide; lisinopril | TABLET;ORAL | 076674-003 | Oct 5, 2004 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Almatica | ZESTORETIC | hydrochlorothiazide; lisinopril | TABLET;ORAL | 019888-001 | Sep 20, 1990 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for hydrochlorothiazide; lisinopril
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Almatica | ZESTORETIC | hydrochlorothiazide; lisinopril | TABLET;ORAL | 019888-002 | Jul 20, 1989 | ⤷ Sign Up | ⤷ Sign Up |
| Merck | PRINZIDE | hydrochlorothiazide; lisinopril | TABLET;ORAL | 019778-003 | Nov 18, 1993 | ⤷ Sign Up | ⤷ Sign Up |
| Merck | PRINZIDE | hydrochlorothiazide; lisinopril | TABLET;ORAL | 019778-001 | Feb 16, 1989 | ⤷ Sign Up | ⤷ Sign Up |
| Merck | PRINZIDE | hydrochlorothiazide; lisinopril | TABLET;ORAL | 019778-002 | Feb 16, 1989 | ⤷ Sign Up | ⤷ Sign Up |
| Almatica | ZESTORETIC | hydrochlorothiazide; lisinopril | TABLET;ORAL | 019888-003 | Nov 18, 1993 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
